HSK-44459

Primary Objectives: 1. To quantitatively analyze the total radioactivity excreted in participants after oral administration of [14C]HSK44459, and to determine the recovery rate and primary excretion pathway of radioactivity in humans; 2. To quantitatively analyze the total radioactivity in whole blood and plasma after a single oral administration of [14C]HSK44459, to determine the pharmacokinetic parameters of total radioactivity in plasma and whole blood (if applicable), and to investigate the distribution of total radioactivity between whole blood and plasma; 3. To investigate the radioactive metabolite profiles in plasma, urine, and feces of participants after oral administration of [14C]HSK44459, to identify the primary metabolites, and to determine the metabolic and elimination pathways. Secondary objectives: 1. To quantitatively analyze the plasma concentrations of parent drug HSK44459, its metabolite HSK46213, and other metabolites (if applicable) using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, and to evaluate the pharmacokinetic parameters of parent drug HSK44459, its metabolite HSK46213, and other metabolites (if applicable) in plasma; 2. To observe the safety of participants after a single dose of [14C]HSK44459.